研究人员认为,患有复发性或顽固性非何杰金淋巴瘤(NHL)的病人对肿瘤学家而言相当于一场历时已久的挑战。随着时间的推移,这些病人出现耐受标准治疗的倾向。但据研究人员在美国奥兰多召开的美国血液学会(ASH)会议上介绍的多项研究结果表明,用以治疗低度的或已转化的低度非何杰金淋巴瘤的新药有可能为这类疾病的治疗提供一种新的重要选择,尤其是可为那些预后状况一般较差的病人提供治疗 Researchers believe that patients with recurrent or refractory non-Hodgkin’s lymphoma (NHL) are equivalent to a long-standing challenge for oncologists. Over time, these patients tended to tolerate standard treatment. However, several studies presented by researchers at the American Society of Hematology (ASH) meeting in Orlando, USA, have shown that new drugs used to treat low-grade or converted non-Hodgkin’s lymphoma are likely to be Treatment of diseases offers a new and important option, especially for patients with poorer prognosis